In March 2021, the FDA-approved the first commercial CAR T-cell therapy, idecabtagene vicleucel (ABECMA), for the indication of relapsed/refractory MM after four or more lines of therapy including an IMiD, PI, and anti-CD38 monoclonal antibody [51]. This evidence concerns the gene CD38 and Miyoshi myopathy.